<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802645</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-CELIM2-050</org_study_id>
    <secondary_id>2011-003288-31</secondary_id>
    <nct_id>NCT01802645</nct_id>
  </id_info>
  <brief_title>Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases</brief_title>
  <acronym>CELIM2</acronym>
  <official_title>Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the following schedules for efficacy with regard to&#xD;
      response rate in neoadjuvant treatment of patients with non-resectable liver metastases:&#xD;
&#xD;
        -  Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and&#xD;
&#xD;
        -  Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with liver metastases from colorectal and without known extrahepatic metastases will&#xD;
      be screened for this study including ras status (b-raf status according to local standard).&#xD;
&#xD;
      Patients receive chemotherapy according to the allocation and are re-evaluated for&#xD;
      resectability every 8 weeks for a maximum of 6 months. Resectable patients will be resected&#xD;
      and receive an adjuvant treatment to complete 12 cycles.&#xD;
&#xD;
      In certain circumstances, a second resection is allowed within the study.&#xD;
&#xD;
      Patients will be randomized using a web-based computer system that allows randomization if&#xD;
      the key basic characteristics are entered.&#xD;
&#xD;
      Patients with ras wild-type tumours will be randomized to receive:&#xD;
&#xD;
        -  Cetuximab/FOLFIRI or&#xD;
&#xD;
        -  Cetuximab/FOLFOXIRI&#xD;
&#xD;
      Patients with ras mutations will be randomized to receive:&#xD;
&#xD;
        -  FOLFOXIRI or&#xD;
&#xD;
        -  FOLFOXIRI/bevacizumab&#xD;
&#xD;
      Chemotherapy doses are adjusted to the risk of toxicity in all treatment arms.&#xD;
&#xD;
      Stratification will be performed according to:&#xD;
&#xD;
        -  Number of metastases (&lt; 5 vs. ≥ 5 metastases)&#xD;
&#xD;
        -  Primary tumour in situ&#xD;
&#xD;
        -  Centre&#xD;
&#xD;
      Treatment regimens For dose reductions and conditions to continue please refer to the full&#xD;
      protocol.&#xD;
&#xD;
      All drugs are used within the label and approved doses.&#xD;
&#xD;
      B-raf mutations are determined according to local standard. If a b-raf mutation is known&#xD;
      before randomization, the investigator can consider the patient as ras wildtype OR as ras&#xD;
      mutant patient.&#xD;
&#xD;
      Cetuximab/FOLFIRI :&#xD;
&#xD;
      Cetuximab 400 mg/m² (first dose, 2 h), then 250 mg/m² (1 h) weekly Irinotecan 180 mg/m², d-l&#xD;
      Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks&#xD;
&#xD;
      Cetuximab/FOLFOXIRI:&#xD;
&#xD;
      Cetuximab 400 mg/m² (first dose, 2 h), then 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² ,&#xD;
      Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2&#xD;
      weeks&#xD;
&#xD;
      FOLFOXIRI:&#xD;
&#xD;
      Irinotecan 165 mg/m², Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200&#xD;
      mg/m² (46 h) every 2 weeks&#xD;
&#xD;
      Bevacizumab/FOLFOXIRI:&#xD;
&#xD;
      Bevacizumab 5 mg/kg (90 - 30 min i.v.), Irinotecan 165 mg/m², Oxaliplatin 85 mg/m² (2 h), d-l&#xD;
      Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks&#xD;
&#xD;
      Evaluation for response and resections Patients are evaluated for response by the same&#xD;
      imaging technique as at baseline every 8 weeks. The findings will be discussed for&#xD;
      resectability within two weeks after tumour assessment in a local multidisciplinary team.&#xD;
&#xD;
      Technically resectable patients should be offered liver resection. The treatment will&#xD;
      continue until liver resection or for a maximum of six months (12 cycles).&#xD;
&#xD;
      Adjuvant treatment After liver resection, an adjuvant treatment is recommended with the same&#xD;
      schedule as preoperatively, for a maximum combined pre- and postoperative treatment of 12&#xD;
      cycles. If less than three postoperative cycles remain, no postoperative treatment will be&#xD;
      started (see chapter 9.10).&#xD;
&#xD;
      Follow up After resection, patients will be followed up for 5 years after randomization. This&#xD;
      includes&#xD;
&#xD;
        -  imaging and clinical investigation every three months for the first 2 years, then every&#xD;
           six months (patients without tumour progression / recurrence)&#xD;
&#xD;
        -  survival status and surgical/medical treatment every three months for the first 2 years&#xD;
           and then every six months (all patients)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Rate of patients with partial or complete response according to modified RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of resected patients without early relaps</measure>
    <time_frame>6 months after resection</time_frame>
    <description>Rate of patients who had a R0 resection of all lesions and are disease free for at least 6 months in the ITT population.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Resection rate, defined as patients with microscopically complete (R0) resection (ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Resection rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Rate of liver resection with macroscopically tumour free margins and/or RFA (all patients with R0 or R1 resection and/or complete RFA of all lesion, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 3 years after randomization</time_frame>
    <description>Progression free survival (Medium, Kaplan-Meier-estimation, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival after resection</measure>
    <time_frame>up to 3 years after resection</time_frame>
    <description>Disease free survival after resection (Medium, Kaplan-Meier-estimation, resected patients)</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 year after randomization</time_frame>
    <description>Overall survival (Kaplan-Meier-estimation, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Toxicity according to NCI-CTC criteria v. 4.0 Perioperative toxicity according to Clavien</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathological response</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Pathological response in the resected tumour tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular markers</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Evaluation of molecular predictive markers for response (i.e. other mutations in EGFR signalling pathway, EGFR ligands) and toxicity</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks&#xD;
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks&#xD;
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks&#xD;
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks&#xD;
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>Leukovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients can be enrolled, if all of these conditions apply:&#xD;
&#xD;
          1. Non-resectable, histologically confirmed, synchronous or metachronous colorectal liver&#xD;
             metastases.&#xD;
&#xD;
          2. Non-resectability will be documented by a local multidisciplinary tumour board with&#xD;
             participation of a surgeon experienced in liver surgery. Patients can be enrolled if&#xD;
             they&#xD;
&#xD;
             a) are technically non-resectable (locally determined by a multi-disciplinary team&#xD;
             discussion based on remaining functional liver tissue after resection, i.e. i)&#xD;
             involvement of both portal veins, all hepatic veins, portal vein of the liver lobe and&#xD;
             hepatic veins draining the segments of the other liver lobe, or ii) other reasons for&#xD;
             less than 30% remaining functional liver tissue after resection) and / or b) have ≥ 5&#xD;
             liver metastases and / or c) are regarded as non-resectable for other reasons&#xD;
             (description necessary)&#xD;
&#xD;
          3. Patients with simultaneous liver metastases are eligible,&#xD;
&#xD;
               1. if the primary tumour was resected at least 1 month prior to chemotherapy or&#xD;
&#xD;
               2. all of the following conditions apply:&#xD;
&#xD;
             i) the primary tumour is clearly resectable, ii) no radiation therapy is planned, iii)&#xD;
             liver resection is planned before resection of the primary or at the same operation as&#xD;
             the resection of the primary, iv) no two-stage liver resection is planned, and v) all&#xD;
             efforts were made to exclude additional distant metastases.&#xD;
&#xD;
          4. WHO PS ≤ 1&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
          6. Adequate bone marrow function, liver function (neutrophils &gt; 1.5 x 109/l; platelets &gt;&#xD;
             100 x 109/l; haemoglobin &gt; 5.0 mmol/l (8.0 g/dl); bilirubin ≤ ULN or ≤ 1.5 x ULN and&#xD;
             not increasing more than 25 % within the last 4 weeks; SGOT and SGPT &lt; 5 x UNL)&#xD;
&#xD;
          7. Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any evidence of extrahepatic metastases, distant lymph node metastases and primary&#xD;
             tumour recurrence&#xD;
&#xD;
          2. (deleted)&#xD;
&#xD;
          3. Prior systemic anti-tumour therapy with anti- EGFR-, anti-angiogenetic drugs or with&#xD;
             chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months or in&#xD;
             combination with radiation as radio sensitizer)&#xD;
&#xD;
          4. Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic&#xD;
             interventions or venous port implantation) ≤ 4 weeks before study entry&#xD;
&#xD;
          5. Renal insufficiency with serum creatinine ≥ 1.5 x UNL. If serum creatinine is between&#xD;
             1.0 and 1.5 x UNL, the creatinine clearance according to the Cockroft-Gault formula&#xD;
             should be ≥ 60 ml/min&#xD;
&#xD;
          6. Hypertension with an arterial blood pressure &gt; 150/90 mmHg&#xD;
&#xD;
          7. Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or&#xD;
             IV, unstable angina pectoris, history of myocardial infarction within the last 12&#xD;
             months, significant arrhythmias)&#xD;
&#xD;
          8. Known proteinuria &gt; 1 g/day (to be tested if proteinuria more than 1+ in the urinary&#xD;
             dipstick analysis)&#xD;
&#xD;
          9. Peripheral neuropathy &gt; CTC grade I&#xD;
&#xD;
         10. Concurrent systemic immune therapy, chemotherapy, hormone therapy, or patients&#xD;
             receiving immune suppressive treatment (i.e. for transplantation, severe rheumatologic&#xD;
             disease)&#xD;
&#xD;
         11. Participation in clinical trials with investigational agents within 30 days before&#xD;
             start of the treatment in study&#xD;
&#xD;
         12. Active treatment of&#xD;
&#xD;
               1. peptic ulcers or bleeding erosive esophagitis / gastritis within 3 months before&#xD;
                  study&#xD;
&#xD;
               2. pulmonary embolism, severe or unstable angina pectoris or myocardial infarction,&#xD;
                  stroke or transient ischemic attack within 12 months before study&#xD;
&#xD;
               3. deep vein thrombosis within 4 weeks before study&#xD;
&#xD;
         13. Inflammatory bowel disease&#xD;
&#xD;
         14. History of other malignancies, from which the patient is not 5 years disease free,&#xD;
             with the exception of colorectal cancer, or adequately treated basal cell or squamous&#xD;
             cell carcinoma of skin or in-situ cervical cancer within 5 years before study&#xD;
&#xD;
         15. History of brain metastases&#xD;
&#xD;
         16. History of severe psychiatric illness&#xD;
&#xD;
         17. Active drug- or alcohol abuse&#xD;
&#xD;
         18. Known hepatitis B or C or HIV infection&#xD;
&#xD;
         19. Breast- feeding or pregnant women&#xD;
&#xD;
         20. Lack of effective contraception (for male and female patients)&#xD;
&#xD;
         21. Known intolerance to one of the following drugs: cetuximab, bevacizumab, oxaliplatin,&#xD;
             irinotecan, 5-FU, folinic acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Folprecht, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital &quot;Carl Gustav Carus&quot; Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis Hämatologie/ Onkologie</name>
      <address>
        <city>Bocholt</city>
        <zip>46397</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie Dülmen GbR</name>
      <address>
        <city>Coesfeld</city>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt/ Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut gGmbH</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum Winnenden</name>
      <address>
        <city>Winnenden</city>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant</keyword>
  <keyword>cetuximab</keyword>
  <keyword>irinotecan</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>5-FU</keyword>
  <keyword>Resection</keyword>
  <keyword>colorectal liver metastases</keyword>
  <keyword>liver resection</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>k-ras</keyword>
  <keyword>non-resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

